P/E ratio for AstraZeneca (AZN)

P/E ratio history for AstraZeneca from 2009 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	21.7	-39.03%	🇺🇸 USA
Novartis NVS	21.8	-38.77%	🇨🇭 Switzerland
Pfizer PFE	19.7	-44.67%	🇺🇸 USA
Abbott Laboratories ABT	29.8	-16.37%	🇺🇸 USA
Eli Lilly LLY	43.0	20.94%	🇺🇸 USA
Sanofi SNY	21.1	-40.63%	🇫🇷 France
Biogen BIIB	16.8	-52.66%	🇺🇸 USA
Merck MRK	15.7	-55.77%	🇺🇸 USA
Bristol-Myers Squibb BMY	20.3	-43.06%	🇺🇸 USA
GSK plc GSK	14.4	-59.51%	🇬🇧 UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.